CEO & President of Protagonist Therapeutics. 38 years of executive, entrepreneural, and scientific experience spanning big pharma & biotechs, and loving it!
𝐉𝐞𝐟𝐟𝐞𝐫𝐢𝐞𝐬 𝐋𝐨𝐧𝐝𝐨𝐧 𝟐𝟎𝟐𝟔: @ProtagonistTx's CEO Dinesh Patel discusses the launch of ICOTYDE, and the company's pipeline, which is well funded now due to commercial success. $PTGX
Full video: https://t.co/6lhIfbpxqK
Protagonist is very pleased to see another global approval for ICOTYDE™ (icotrokinra)!
ICOTYDE, co-discovered by Protagonist and Johnson & Johnson scientists, has now been approved in the United Kingdom for adults and adolescents with moderate-to-severe plaque psoriasis.
This latest approval builds on approvals in the U.S., China, and EU, bringing ICOTYDE to more patients around the world.
https://t.co/NtRtGJ2GPL
#ICOTYDE #PeptideTherapeutics #PTGX
From Local to Global; gratifying to see #MIMRYLO reaching to patients globally. Big Congrats to our partner @TakedaPharma. A huge motivator for team @ProtagonistTx to keep doing what it does best; inventing new medicine to address unmet needs globally. Cheers!
MIMRYLO™ (rusfertide) has been approved in the United Arab Emirates for adults with Polycythemia Vera (PV).
The Protagonist team is very pleased to see MIMRYLO reaching more patients around the world.
#PolycythemiaVera#RareDisease#BloodCancer
https://t.co/cDEMD0K708
From local to global; very pleased to see ICOTYDE expanding its outreach. Best news for psoriasis patients who prefer a safe and effective needle-free treatment with the convenience of a once daily oral pill.
This week, the European Commission approved ICOTYDE™ (icotrokinra) for adults and adolescents with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
Following approvals in the U.S. and China, European approval represents another important step in the global expansion of ICOTYDE — and further demonstrates the potential of targeted oral peptides to become an important new therapeutic option for patients worldwide.
https://t.co/oGezFbpL2z
#ICOTYDE #PeptideTherapeutics #PTGX
A new chapter in #PolycythemiaVera treatment begins.
The FDA has approved MIMRYLO™ (rusfertide), the first hepcidin mimetic for erythrocytosis in adults with PV.
What patients should know:
https://t.co/FNUp2WqdBs
#BloodCancerAwarenessMonth#Mimrylo
The FDA approval of MIMRYLO™ (rusfertide) marks the culmination of more than a decade of work at Protagonist.
Members of our team reflect on the journey and the patients, investigators, partners, and colleagues who helped make it possible.
#PTGX#FDAApproval#PV
China’s drug regulator has approved #ICOTYDE for moderate-to-severe plaque psoriasis.
ICOTYDE continues to demonstrate the power of our peptide discovery platform and long-term collaboration with Johnson & Johnson. With approvals now in the U.S. and China, we look forward to the European Commission’s decision and the potential to bring this differentiated oral therapy to more patients globally.
https://t.co/0BqEMv7KyT
#Psoriasis #IL23 #OralPeptides
It was great to join @SchwabNetwork last Friday. Thanks to the Schwab team for having me, and to the entire @ProtagonistTx team whose non-stop hard work continues to move our company forward and advance new medicines for patients.
Today, ICOTYDE™ was nominated for the 2026 #PrixGalien USA Award for Best Pharmaceutical Product.
This recognition by @GalienFdn highlights the scientific innovation behind the first and only FDA-approved targeted oral peptide designed to block the IL-23 receptor, bringing a novel plaque psoriasis treatment approach that combines the established efficacy and safety of IL-23 pathway blockade with the convenience of a once-daily oral pill.
We’re gratified to see an innovation that began at Protagonist being recognized among this year's nominees and congratulate our colleagues at Johnson & Johnson, the Protagonist team, clinical investigators, and the patients who helped make this possible.
#PeptideTherapeutics #DrugDiscovery #Innovation
https://t.co/1NMC1pkQzq
11,000 patients initiated. 18,000+ prescriptions written. 6,000 unique prescribers. More than 50% commercial coverage within 90 days. These are some of the metrics behind the early momentum of #ICOTYDE, as shared in Johnson & Johnson’s Q2 earnings call this morning.
We are encouraged by the strong early momentum and excited about what lies ahead.
Hear more from Johnson & Johnson’s Q2 earnings call: https://t.co/QDjz5m7djt
#PTGX #PeptideTherapeutics
@CNBCFastMoney@ProtagonistTx It was such an honor to be on Melissa Lee’s CNBC fast money show today. Sincere thanks to team @ProtagonistTx for creating this level of credibility and visibility. We just keep moving forward relentlessly. Cheers!
Rusfertide, currently under a priority NDA review at FDA, is the outcome of a research program initiated at @ProtagonistTx in 2012. By opting-out of further co-development and co-commercialization, we place the company in an even stronger financial position while benefiting patients, our shareholders, and @TakedaPharma. Eagerly awaiting the potential approval in third quarter. Cheers!
Protagonist has exercised its right to opt out of the 50:50 U.S. profit and loss sharing arrangement under our worldwide license and collaboration agreement with Takeda for rusfertide, an investigational first-in-class hepcidin mimetic peptide. Rusfertide is now under U.S. Food and Drug Administration (FDA) Priority Review for the treatment of adults with polycythemia vera (PV).
Read more: https://t.co/mAWPAFZlw4
What a week for all of us at Protagonist! After celebrating the FDA Approval of ICOTYDE, we are thrilled to be recognized on the Nasdaq Tower in Times Square as a Fast 500 company. Ranking among the fastest-growing innovative companies in North America is a powerful validation of our innovation platform. To our customers, partners, and every member of the Protagonist family: This moment belongs to you. We’re just getting started. Looking forward to what's yet to come.
#PTGX #NASDAQ #BayAreaFast500 #Biotech #Innovation
Congrats dad (@ProtagonistCEO)!
I'm *so* proud of what you and the @ProtagonistTx team have achieved. 13yrs end-to-end from R&D to full FDA approval for a new drug. It's inspiring.